Company: HURA
Filing Date: 2025-02-07
Form Type: S-4
Source: 0001193125-25-022803
Chunk: 645

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-02-07
Form: S-4
Chunk 645
---
 |

The cash component of the aggregate merger consideration in the Business Combination will be a base cash amount of approximately $9,005,000 (consisting of a value of $15,000,000 minus the approximate $5,995,000 advanced to Kineta under the Exclusivity, Right of First Offer, and CTF Agreements) less the sum of Kineta’s working capital deficit at the closing of the Proposed Transaction and any working capital loans made by TuHURA to Kineta between the signing of the Merger Agreement and closing of the Mergers. The share component of the aggregate merger consideration in the Business Combination will consist of an aggregate of up to approximately 3,476,566 shares of TuHURA common stock, subject to a six-monthholdback of approximately 869,141 of such shares to satisfy certain additional liabilities of the closing date that may be identified after the closing. As additional merger consideration in the Business Combination, Kineta stockholders will be entitled to receive their pro rata share of certain payments that Kineta may receive after the closing from the potential pre-closingsale by Kineta of certain non-KVA12123products and technologies. 419

NOTES TO UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION TuHURA and Kineta CTF Agreement In connection with the New Merger Agreement, TuHURA and Kineta entered into a Clinical Trial Funding Agreement under which TuHURA agreed to continue to fund clinical trial expenses for KVA12123 in an additional amount of up to $900,000, excluding the Existing Advances already financed, which may be increased upon mutual agreement. The New Merger Agreement also provides that Kineta may request the extension of up to $2,000,000 in working capital loans from TuHURA, $1,750,000 of which will be contingent on the completion of a financing transaction by TuHURA (the “Concurrent Investment”). TuHURA Concurrent Investment In connection with the Merger Agreement and as a condition precedent to the completion of the Mergers, the Company plans to enter into subscription agreements with interested investors to purchase TuHURA Common Stock for net proceeds of at least $35 million. TuHURA has not currently executed any subscription agreement in connection with the contemplated Concurrent Investment. The Concurrent Investment is presented in the unaudited pro forma condensed combined financial statement as contemplated since it is a condition of closing of the Mergers. The Concurrent Investment is currently estimated for purposes of